Functionalized Liposome and Albumin-Based Systems As Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Feb 25

PMID 35203695

Authors

Sofia Teixeira

Maria Alice Carvalho

Elisabete M S Castanheira

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the leading causes of death worldwide. In the available treatments, chemotherapy is one of the most used, but has several associated problems, namely the high toxicity to normal cells and the resistance acquired by cancer cells to the therapeutic agents. The scientific community has been battling against this disease, developing new strategies and new potential chemotherapeutic agents. However, new drugs often exhibit poor solubility in water, which led researchers to develop functionalized nanosystems to carry and, specifically deliver, the drugs to cancer cells, targeting overexpressed receptors, proteins, and organelles. Thus, this review is focused on the recent developments of functionalized nanosystems used to carry poorly water-soluble drugs, with special emphasis on liposomes and albumin-based nanosystems, two major classes of organic nanocarriers with formulations already approved by the U.S. Food and Drug Administration (FDA) for cancer therapeutics.

Citing Articles

PEG-Polymeric Nanocarriers Alleviate the Immunosuppressive Effects of Free 4-Thiazolidinone-Based Chemotherapeutics on T Lymphocyte Function and Cytokine Production.

Tulinska J, Kobylinska L, Lehotska Mikusova M, Babincova J, Mitina N, Rollerova E Int J Nanomedicine. 2025; 19:14021-14041.

PMID: 39742092 PMC: 11687095. DOI: 10.2147/IJN.S479137.

Edge advances in nanodrug therapies for osteoarthritis treatment.

Liao J, Gu Q, Liu Z, Wang H, Yang X, Yan R Front Pharmacol. 2024; 15:1402825.

PMID: 39539625 PMC: 11559267. DOI: 10.3389/fphar.2024.1402825.

An Overview of Advances in Rare Cancer Diagnosis and Treatment.

Christyani G, Carswell M, Qin S, Kim W Int J Mol Sci. 2024; 25(2).

PMID: 38256274 PMC: 10815984. DOI: 10.3390/ijms25021201.

Design-of-Experiment-Assisted Fabrication of Biodegradable Polymeric Nanoparticles: In Vitro Characterization, Biological Activity, and In Vivo Assessment.

Mir M, Akhter M, Afzal O, Rab S, Altamimi A, Alossaimi M ACS Omega. 2023; 8(42):38806-38821.

PMID: 37901564 PMC: 10601053. DOI: 10.1021/acsomega.3c01153.

Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity.

Liang T, Feng Z, Zhang X, Li T, Yang T, Yu L Front Bioeng Biotechnol. 2023; 11:1266888.

PMID: 37811375 PMC: 10551635. DOI: 10.3389/fbioe.2023.1266888.

References

Singh A, Biswas A, Shukla A, Maiti P . Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 2019; 4:33. PMC: 6799838. DOI: 10.1038/s41392-019-0068-3. View

Tao C, Chuah Y, Xu C, Wang D . Albumin conjugates and assemblies as versatile bio-functional additives and carriers for biomedical applications. J Mater Chem B. 2020; 7(3):357-367. DOI: 10.1039/c8tb02477d. View

Kiaie S, Mojarad-Jabali S, Khaleseh F, Allahyari S, Taheri E, Zakeri-Milani P . Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives. Int J Pharm. 2020; 581:119269. DOI: 10.1016/j.ijpharm.2020.119269. View

Bhakay A, Rahman M, Dave R, Bilgili E . Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation⁻Processing Aspects and Challenges. Pharmaceutics. 2018; 10(3). PMC: 6160929. DOI: 10.3390/pharmaceutics10030086. View

Li J, Cheng X, Chen Y, He W, Ni L, Xiong P . Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro evaluation. Int J Pharm. 2016; 512(1):262-272. DOI: 10.1016/j.ijpharm.2016.08.037. View

Yan M, Schwaederle M, Arguello D, Millis S, Gatalica Z, Kurzrock R . HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015; 34(1):157-64. PMC: 4368842. DOI: 10.1007/s10555-015-9552-6. View

Dong Y, Fu R, Yang J, Ma P, Liang L, Mi Y . Folic acid-modified ginsenoside Rg5-loaded bovine serum albumin nanoparticles for targeted cancer therapy in vitro and in vivo. Int J Nanomedicine. 2019; 14:6971-6988. PMC: 6718740. DOI: 10.2147/IJN.S210882. View

Ge L, You X, Huang J, Chen Y, Chen L, Zhu Y . Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy. Front Pharmacol. 2018; 9:582. PMC: 6005878. DOI: 10.3389/fphar.2018.00582. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Woitok M, Klose D, Niesen J, Richter W, Abbas M, Stein C . The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. Cancer Lett. 2016; 381(2):323-30. DOI: 10.1016/j.canlet.2016.08.003. View

11.

Chen S, Wu J, Tang Q, Xu C, Huang Y, Huang D . Nano-micelles based on hydroxyethyl starch-curcumin conjugates for improved stability, antioxidant and anticancer activity of curcumin. Carbohydr Polym. 2019; 228:115398. DOI: 10.1016/j.carbpol.2019.115398. View

12.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

13.

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

14.

Liu L, Bi Y, Zhou M, Chen X, He X, Zhang Y . Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers. ACS Appl Mater Interfaces. 2017; 9(8):7424-7435. DOI: 10.1021/acsami.6b14390. View

15.

Fang Y, Chuang C, Wu Y, Lin H, Lu Y . SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. Int J Nanomedicine. 2018; 13:2789-2802. PMC: 5955381. DOI: 10.2147/IJN.S158426. View

16.

Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V . Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Deliv. 2018; 25(1):517-532. PMC: 6058534. DOI: 10.1080/10717544.2018.1435747. View

17.

Zhang Z, Yang J, Min Q, Ling C, Maiti D, Xu J . Holo-Lactoferrin Modified Liposome for Relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer. Small. 2019; 15(6):e1803703. DOI: 10.1002/smll.201803703. View

18.

Shin D, Kwon G . Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy. Int J Pharm. 2017; 518(1-2):307-311. PMC: 5267929. DOI: 10.1016/j.ijpharm.2017.01.006. View

19.

Li X, Diao W, Xue H, Wu F, Wang W, Jiang B . Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma. Cancer Lett. 2020; 489:163-173. DOI: 10.1016/j.canlet.2020.06.017. View

20.

Pireddu R, Pibiri M, Valenti D, Sinico C, Fadda A, Simbula G . A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Int J Pharm. 2018; 537(1-2):257-267. DOI: 10.1016/j.ijpharm.2017.12.048. View